ES2154728T3 - Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2. - Google Patents

Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.

Info

Publication number
ES2154728T3
ES2154728T3 ES95914838T ES95914838T ES2154728T3 ES 2154728 T3 ES2154728 T3 ES 2154728T3 ES 95914838 T ES95914838 T ES 95914838T ES 95914838 T ES95914838 T ES 95914838T ES 2154728 T3 ES2154728 T3 ES 2154728T3
Authority
ES
Spain
Prior art keywords
rejection
hla
precursors
antigen
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914838T
Other languages
English (en)
Spanish (es)
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Der Bruggen Pierrce Van
Pierre Coulie
Thomas Gajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
University of Oxford
Universiteit Leiden
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
University of Oxford
Universiteit Leiden
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Institute for Cancer Research Ltd, University of Oxford, Universiteit Leiden, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2154728T3 publication Critical patent/ES2154728T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES95914838T 1994-03-24 1995-03-22 Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2. Expired - Lifetime ES2154728T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof

Publications (1)

Publication Number Publication Date
ES2154728T3 true ES2154728T3 (es) 2001-04-16

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914838T Expired - Lifetime ES2154728T3 (es) 1994-03-24 1995-03-22 Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.

Country Status (16)

Country Link
US (1) US5851523A (de)
EP (2) EP0960622A3 (de)
JP (1) JP3536179B2 (de)
CN (1) CN1151170C (de)
AT (1) ATE198336T1 (de)
AU (1) AU698781B2 (de)
CA (1) CA2186004C (de)
DE (1) DE69519748T2 (de)
DK (1) DK0804483T3 (de)
ES (1) ES2154728T3 (de)
FI (1) FI963779A0 (de)
GR (1) GR3035636T3 (de)
NO (1) NO963919L (de)
NZ (1) NZ283587A (de)
PT (1) PT804483E (de)
WO (1) WO1995025740A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
DE69610483T2 (de) * 1996-01-18 2001-06-13 Aventis Pharma Deutschland Gmbh In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
WO1998058951A1 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (de) * 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Komplexe aus säugetier-interleukin-12 p40 und interleukin b30, antikörper, verwendung in pharmazeutischen zusammensetzungen
KR100894359B1 (ko) * 1999-09-09 2009-04-22 쉐링 코포레이션 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
EP1222274A2 (de) * 1999-10-19 2002-07-17 Ludwig Institute For Cancer Research Vom mage-12 abgeleitete antigene peptide und deren verwendungen
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
EP2188017A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von glucagon (1-29) allein oder in kombination mit neuropeptid w30 als therapeutisches mittel
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)

Also Published As

Publication number Publication date
DK0804483T3 (da) 2001-02-12
CN1150805A (zh) 1997-05-28
PT804483E (pt) 2001-06-29
EP0960622A3 (de) 1999-12-22
JP3536179B2 (ja) 2004-06-07
EP0804483A4 (de) 1998-05-20
DE69519748D1 (de) 2001-02-01
NO963919L (no) 1996-11-20
CN1151170C (zh) 2004-05-26
WO1995025740A1 (en) 1995-09-28
ATE198336T1 (de) 2001-01-15
US5851523A (en) 1998-12-22
EP0804483B1 (de) 2000-12-27
CA2186004C (en) 2008-09-23
FI963779L (fi) 1996-09-23
AU698781B2 (en) 1998-11-05
AU2192895A (en) 1995-10-09
NO963919D0 (no) 1996-09-19
FI963779A7 (fi) 1996-09-23
EP0960622A2 (de) 1999-12-01
NZ283587A (en) 1998-04-27
FI963779A0 (fi) 1996-09-23
JPH10504518A (ja) 1998-05-06
CA2186004A1 (en) 1995-09-28
EP0804483A1 (de) 1997-11-05
DE69519748T2 (de) 2001-10-18
GR3035636T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
ES2154728T3 (es) Peptidos aislados derivados de precursores del antigeno de rechazo de tumores mage que forman un complejo con moleculas del hla-a2.
ES2135051T3 (es) Peptidos derivados de mage-3, aislados, que forman complejos con moleculas hla-a2 y usos de los mismos.
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
ES2142790T3 (es) Epitopos antigenicos presentes sobre iga unida a la membrana pero no secretada.
MX6887E (es) Procedimiento mejorado para la conversion del metano en hidrocarburos de mayor peso molecular
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
IT942119B (it) Procedimento per produrre idrati di alogeni e batteria elettrica che ne fa uso
DD129997A5 (de) Verfahren zur herstellung neuer antibiotischer praeparate zur pharmazeutischen verwendung
NL7609992A (nl) Werkwijze voor het bereiden van synthesegas.
ES490304A0 (es) Procedimiento para la recuperacion de gas metano de yacimi- entos subterraneos
DD135899A5 (de) Verfahren zur herstellung neuer zyklopropankarbonsaeuren
NL7709025A (nl) Werkwijze ter bereiding van allergeenhoudende stof- fen.
IT1065217B (it) Procedimento per la fabbricazione di materiali fibrosi piatti imitanti il cuoio naturale
NL7710520A (nl) Werkwijze voor de elektrolytische bereiding van joodwaterstof.
DE69030494D1 (de) Karzinomverwandtes haptoglobin (hpr)
NL7713058A (nl) Werkwijze ter bereiding van monoalkylsulfaten.
ES488301A0 (es) Procedimiento para la obtencion de dehidropeptidos
DD129105A5 (de) Verfahren zur herstellung neuer thiophosphate
AT355340B (de) Optisches instrument, insbesondere fernglas, und verfahren zu dessen herstellung
ES2061731T3 (es) Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos.
NL7605883A (nl) Werkwijze voor het omzetten van synthesegas in koolwaterstofmengsels.
DK207375A (da) Fnug af syntese-fibre samt fremgangsmade til disses fremstilling
CH621029B (de) Verfahren zur herstellung sekundaerer aetheraminacetate und ihre verwendung als praeparationsmittel fuer synthesefasern.
SU546751A1 (ru) Замок дл креплени штанг к рамам

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 804483

Country of ref document: ES